A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).

Autor: Olander KW; University Eye Specialists, Maryville, TN., Sato MA; East West Eye Institute, Los Angeles, CA., Abrams MA; Abrams Eye Center, Cleveland, OH., Jerkins GW; Advancing Vision Research, Nashville, TN., Lu F; Santen Inc., Emeryville, CA., Dinh P; Santen Inc., Emeryville, CA., Odani-Kawabata N; Santen Inc., Emeryville, CA.; Santen Pharmaceutical Co., Ltd., Osaka, Japan., Chabi A; Santen Inc., Emeryville, CA., Shams NK; Santen Inc., Emeryville, CA.; Santen Pharmaceutical Co., Ltd., Osaka, Japan.

Publikováno v: Journal of glaucoma [J Glaucoma] 2021 Jun 01; Vol. 30 (6), pp. 473-480.

Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.

Autor: Aihara M; Department of Ophthalmology, University of Tokyo, Bunkyo-ku, Tokyo, Japan., Lu F; Santen Inc., Emeryville, California, USA. Electronic address: fenghe_lu@hotmail.com., Kawata H; Santen Pharmaceutical Co. Ltd., Osaka, Japan., Iwata A; Santen Inc., Emeryville, California, USA; Santen Pharmaceutical Co. Ltd., Osaka, Japan., Odani-Kawabata N; Santen Inc., Emeryville, California, USA; Santen Pharmaceutical Co. Ltd., Osaka, Japan., Shams NK; Santen Inc., Emeryville, California, USA; Santen Pharmaceutical Co. Ltd., Osaka, Japan.

Publikováno v: American journal of ophthalmology [Am J Ophthalmol] 2020 Dec; Vol. 220, pp. 53-63. Date of Electronic Publication: 2020 Jun 10.

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells.

Autor: Yamamoto Y; Research and Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan., Taniguchi T; Research and Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan., Inazumi T; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Iwamura R; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan., Yoneda K; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan., Odani-Kawabata N; Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan.; Research and Development Division, Santen, Inc., Emeryville, California., Matsugi T; Research and Development Division, Santen Pharmaceutical Co., Ltd., Nara, Japan., Sugimoto Y; Department of Pharmaceutical Biochemistry, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan., Shams NK; Research and Development Division, Santen, Inc., Emeryville, California.

Publikováno v: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2020 Apr; Vol. 36 (3), pp. 162-169. Date of Electronic Publication: 2020 Jan 14.

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).

Autor: Aihara M; Department of Ophthalmology, University of Tokyo, Bunkyo-ku, Japan., Lu F; Santen, Inc., Emeryville, California., Kawata H; Santen Pharmaceutical Co., Ltd., Osaka, Japan., Tanaka Y; Santen Pharmaceutical Co., Ltd., Osaka, Japan., Yamamura K; Santen Pharmaceutical Co., Ltd., Ikoma, Japan., Odani-Kawabata N; Santen, Inc., Emeryville, California.; Santen Pharmaceutical Co., Ltd., Osaka, Japan., Shams NK; Santen, Inc., Emeryville, California.; Santen Pharmaceutical Co., Ltd., Osaka, Japan.

Publikováno v: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2019 Dec; Vol. 35 (10), pp. 542-550. Date of Electronic Publication: 2019 Nov 01.

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.

Autor: Fuwa M; 1 R&D Division, Santen Pharmaceutical Co., Ltd. , Nara, Japan ., Toris CB; 2 Department of Ophthalmology, Nebraska Medical Center, University of Nebraska Medical Center , Omaha, Nebraska.; 3 Department of Ophthalmology, Case Western Reserve University , Cleveland, Ohio., Fan S; 2 Department of Ophthalmology, Nebraska Medical Center, University of Nebraska Medical Center , Omaha, Nebraska., Taniguchi T; 1 R&D Division, Santen Pharmaceutical Co., Ltd. , Nara, Japan ., Ichikawa M; 1 R&D Division, Santen Pharmaceutical Co., Ltd. , Nara, Japan ., Odani-Kawabata N; 4 R&D Division, Santen Pharmaceutical Co., Ltd. , Osaka, Japan ., Iwamura R; 5 Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd. , Yamaguchi, Japan ., Yoneda K; 5 Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd. , Yamaguchi, Japan ., Matsugi T; 1 R&D Division, Santen Pharmaceutical Co., Ltd. , Nara, Japan ., Shams NK; 4 R&D Division, Santen Pharmaceutical Co., Ltd. , Osaka, Japan .; 6 R&D Division, Santen, Inc. , Emeryville, California., Zhang JZ; 1 R&D Division, Santen Pharmaceutical Co., Ltd. , Nara, Japan .; 6 R&D Division, Santen, Inc. , Emeryville, California.

Publikováno v: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2018 Sep; Vol. 34 (7), pp. 531-537. Date of Electronic Publication: 2018 Jul 10.